Reporte zur Charge BIV GH 9694

Symptomtext

Feverish; Achy; Headache; The patient received fourth (booster) dose of BNT162B2; The patient received fourth (booster) dose of BNT162B2; This is a spontaneous report received from a contactable reporter (consumer or other non-HCP). A 13-year-old female patient (not pregnant) received bnt162b2 (BNT162B2) on 07Sep2022 as dose 4 (booster), single (Lot number: BIV GH 9694) at the age of 13 years, Intramuscular in left arm for COVID-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Bnt162b2 (DOSE 1, SINGLE; Lot number: EN5318), administration date: 12May2021, when the patient was 12 years old, for COVID-19 immunisation; Bnt162b2 (DOSE 2, SINGLE; Lot number: EW0185), administration date: 02Jun2021, when the patient was 12 years old, for COVID-19 immunisation and Bnt162b2 (DOSE 3 (BOOSTER), SINGLE; Lot number: FJ5683), administration date: 10Jan2022, when the patient was 12 years old, for COVID-19 immunisation. The following information was reported: OFF LABEL USE (non-serious), IMMUNISATION (non-serious) all with onset 07Sep2022, outcome "unknown", and all described as "The patient received fourth (booster) dose of BNT162B2"; PYREXIA (non-serious) with onset 08Sep2022, outcome "recovering", described as "Feverish"; PAIN (non-serious) with onset 08Sep2022, outcome "recovering", described as "Achy"; HEADACHE (non-serious) with onset 08Sep2022, outcome "recovering". Therapeutic measures were taken as a result of pyrexia, pain and headache. Additional information: The patient had no known allergies. Prior to vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccine within four weeks prior to the COVID vaccine. The events did not result in doctor or other health care professional office/clinic visit, and emergency room/department or urgent care. Treatment included ADVIL for pyrexia, pain and headache. Since the vaccination, the patient had not been tested for COVID-19.